- Home
- AIM vs VISL Comparison
AIM vs VISL Comparison
Compare AIM & VISL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- VISL
- Stock Information
- Founded
- AIM 1966
- VISL 2002
- Country
- AIM United States
- VISL United States
- Employees
- AIM N/A
- VISL N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- VISL Telecommunications Equipment
- Sector
- AIM Health Care
- VISL Telecommunications
- Exchange
- AIM Nasdaq
- VISL Nasdaq
- Market Cap
- AIM 15.9M
- VISL 14.9M
- IPO Year
- AIM N/A
- VISL N/A
- Fundamental
- Price
- AIM $0.22
- VISL $4.35
- Analyst Decision
- AIM Strong Buy
- VISL
- Analyst Count
- AIM 2
- VISL 0
- Target Price
- AIM $3.00
- VISL N/A
- AVG Volume (30 Days)
- AIM 295.4K
- VISL 22.1K
- Earning Date
- AIM 11-15-2024
- VISL 11-14-2024
- Dividend Yield
- AIM N/A
- VISL N/A
- EPS Growth
- AIM N/A
- VISL N/A
- EPS
- AIM N/A
- VISL N/A
- Revenue
- AIM $190,000.00
- VISL $32,438,000.00
- Revenue This Year
- AIM N/A
- VISL $30.41
- Revenue Next Year
- AIM $1,086.80
- VISL $11.96
- P/E Ratio
- AIM N/A
- VISL N/A
- Revenue Growth
- AIM N/A
- VISL 19.86
- 52 Week Low
- AIM $0.21
- VISL $2.77
- 52 Week High
- AIM $0.62
- VISL $8.15
- Technical
- Relative Strength Index (RSI)
- AIM 35.93
- VISL 26.02
- Support Level
- AIM $0.24
- VISL $3.70
- Resistance Level
- AIM $0.27
- VISL $6.74
- Average True Range (ATR)
- AIM 0.02
- VISL 0.45
- MACD
- AIM -0.00
- VISL -0.16
- Stochastic Oscillator
- AIM 7.49
- VISL 21.38
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About VISL Vislink Technologies Inc.
Vislink Technologies Inc is a technology business specializing in collecting, delivering, and managing high-quality, live video and associated data from the scene of the action to the viewing screen. It provides solutions for the collection of live news, sports, and entertainment events for the broadcast markets. It also furnishes the surveillance and defense markets with real-time video intelligence solutions using various tailored transmission products. The company provides professional and technical services utilizing a staff of technology experts with decades of applied knowledge and real-world experience in terrestrial microwave, satellite, fiber optic, surveillance, and wireless communications systems delivering a broad spectrum of customer solutions.